NCT03006172
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03006172
Title To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Genentech, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | GBR | FRA | ESP | CAN

Facility Status City State Zip Country Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Columbia University Medical Center New York New York 10032 United States Details
SCRI Oncology Partners Nashville Tennessee 37203 United States Details
Princess Margaret Hospital Toronto Ontario M5G2M9 Canada Details
Institut Bergonie Bordeaux 33076 France Details
Institut Gustave Roussy Villejuif 94805 France Details
Hospital Universitari Vall d'Hebron Barcelona 08035 Spain Details
Royal Marsden Hospital - Surrey Surrey Sutton SM2 5PT United Kingdom Details
St Bartholomew's Hospital London EC1 A7BE United Kingdom Details
Royal Marsden Hospital - London London SW3 6JJ United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field